Kisqali

Active Ingredient(s): Ribociclib
FDA Approved: * March 13, 2017
Pharm Company: * NOVARTIS PHARMS CORP
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Kisqali Overview

Ribociclib, sold under the brand name Kisqali & Kryxana both marketed by Novartis,[1][2] is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer.[3] Ribociclib is a kinase inhibitor indicated in combination with: an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative...

Read more Kisqali Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ribociclib

Recent Kisqali Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ribociclib
  • Tablet: 200mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Kisqali: (3 results)

Sorted by National Drug Code
  • 0078-0860 Kisqali 200 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation
  • 0078-0867 Kisqali 200 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation
  • 0078-0874 Kisqali 200 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation

Other drugs which contain Ribociclib or a similar ingredient: (1 result)